New triple combination therapy boosting CRC survival rates

Pharmaceutical companies Pierre Fabre and Array BioPharma conducted a phase III trial evaluating a triple combination therapy for metastatic colorectal cancer patients, Labiotech reports.

Researchers used a combination of encorafenib, binimetinib and cetuximab to treat CRC. Encorafenib prevents mutant enzymes from stimulating cell growth, binimetinib brings those mutated enzymes under control to regulate proliferation and cetuximab binds the epidermal growth factor receptor.

When used together the three therapies improved progression-free survival rates in 30 patients for whom previous treatments were ineffective. Specifically, 48 percent of patients had a reduction in tumor size, with three patients completely eradicating their cancers.

The study did not provide an overall survival rate, however.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast